Human Microbiome Market Size, Growth, Share & Trends Analysis
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
USD 7.09 BN
MARKET SIZE,
CAGR 31.0%
(2025-2031)
375
REPORT PAGES
414
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The human microbiome market is projected to reach USD 7.09 billion by 2031 from USD 1.40 billion in 2025, at a CAGR of 31.0% from 2025 to 2031. The human microbiome encompasses the collective genetic material of diverse microorganisms residing within the human body, known as the metagenome. This includes bacteria, fungi, protozoans, non-living viruses, and various single-celled organisms. These microorganisms play a crucial role in human physiology, influencing metabolic and immune functions. Found within human tissues, the microbiome is a focal point of research for medical advancements and analytical techniques. It is applied in probiotics, prebiotics, pharmaceuticals, and therapeutic systems to address conditions such as diabetes, obesity, and cancer, as well as a range of metabolic, gastrointestinal, neurological, central nervous system, and autoimmune disorders. Market growth is driven by collaborative initiatives between organizations and academia to develop new microbiome-based products and therapies. Additionally, the rising number of startups and SMEs is actively contributing to the development of microbiome-based therapeutics, which further supports market growth.
KEY TAKEAWAYS
- North America accounted for the largest share of 47.5% of the human microbiome market in 2024.
- By product, the supplements market segment currently dominate the market in 2024 with a share of 77.2%
- By type, the bacterial consortia transplant (BCT)/fecal microbiota transplant (FMT) segment leads the market with a share of 69.8% in 2024.
- By disease, the infectious diseases segment is the fastest-growing segment in the human microbiome diagnostics & therapeutics market, growing at a CAGR of 35.2% in the forecast period.
- By route of administration, the rectal route of administration segment is expected to be the fastest-growing segment in the global human microbiome market.
- Hospitals & clinics, long-term care facilities, and other end users (such as retail pharmacies, online channels, and health stores) drive market demand. Hospitals & clinics dominate due to the rising adoption of microbiome-based therapies in clinical settings.
- Services include strain development & optimization, fermentation & downstream processing, formulation & fill/finish, and other services (analytical testing, QC, and sequencing). The fermentation & downstream processing segment is a major segment, supporting large-scale commercialization of microbiome products.
- Seres Therapeutics, Ferring B.V., International Flavors & Fragrances Inc. and BioGaia were identified as some of the star players in the human microbiome market (global), given their strong market share and product footprint.
- Companies such as, Guangzhou Zhiyi Biotechnology Co., Ltd., NuBiyota, OxThera have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
The human microbiome market is poised for strong growth over the coming years, fueled by rising awareness of the critical role of microbiota in human health and disease management. Advances in microbiome research and therapeutics are driving innovation in areas such as gastrointestinal health, infectious diseases, metabolic disorders, and personalized medicine. The growing demand for probiotics, prebiotics, and microbiome-based drugs is expanding the market’s footprint across pharmaceuticals, nutraceuticals, and diagnostics. With increasing investments in clinical trials, regulatory support, and consumer preference for natural and preventive health solutions, the human microbiome is emerging as a transformative field that underpins the next wave of healthcare innovation.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on consumers’ business in the human microbiome market is shaped by technological advancements and emerging therapeutic approaches. Innovations such as sequencing, phage therapy, engineered consortia, and CRISPR-based editing are creating new revenue streams, driving healthcare transformation, and expanding opportunities for microbiome product manufacturers.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Collaborative initiatives between organizations and academia in microbiome industry
-
Increasing number of start-ups/SMEs exploring microbiome niche
RESTRAINTS
Impact
Level
Level
-
Adverse impact of complex regulatory policies on commercialization of microbiomes
-
High investments in commercialization of microbiome drugs
OPPORTUNITIES
Impact
Level
Level
-
Increasing demand for personalized medicine
-
Emergence of postbiotics
CHALLENGES
Impact
Level
Level
-
Slow patient adoption of microbiome-based therapies
-
Complexities involved in development of microbiome therapies
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
DRIVER: Advancements in microbiome sequencing
The rapid adoption of advanced sequencing methods such as 16S rRNA, nanopore, and whole-genome sequencing is accelerating microbiome research and therapeutics. These technologies provide precise microbial profiling, uncover complex microbiota–health relationships, and enable the development of targeted therapies and personalized treatments across infectious, metabolic, and immune-related disorders.
RESTRAINT: High investments in commercializing microbiome drugs
The commercialization of microbiome drugs faces significant challenges due to high development costs, complex GMP requirements, and the need for specialized handling of live organisms. Establishing cGMP facilities, ensuring batch consistency, and conducting long, uncertain clinical trials increase financial risks. These barriers limit large-scale adoption and slow the transition from research to approved therapeutic products.
OPPORTUNITY: Increasing demand for personalized medicine
The growing shift toward personalized medicine is creating significant opportunities in the human microbiome market. By tailoring treatments based on individual microbiome profiles, personalized therapies enable targeted disease prevention and management. These approaches enhance treatment efficacy, reduce adverse effects, and support the development of innovative microbiome-based interventions across gastrointestinal, metabolic, and immune-related disorders.
CHALLENGE: Slow patient adoption of microbiome-based therapies
The adoption of microbiome-based therapies remains limited due to low awareness among patients and healthcare providers, inconsistent clinical evidence, and variability in product quality. High costs, regulatory uncertainties, and the need for personalized approaches further slow integration into mainstream healthcare.
Human Microbiome Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Ostia Sciences announced a collaboration with Expert’Biome (a CDMO by Lallemand) to support process development and clinical-grade production for an oral care probiotic program. | Demonstrates incremental build-out of capacity via CDMO partnerships instead of investing in new facilities | Accelerates time to clinic by leveraging an established GMP partner | Reduces upfront capital burden for smaller biotech players |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The ecosystem for the human microbiome market comprises major players offering human microbiome products & services, regulatory authorities, and end users, such as academic & research institutes, hospitals & clinics, long-term care facilities, and other end users. These stakeholders interact and collaborate to drive growth and innovation in the human microbiome landscape.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Human Microbiome Market, By Product
By product, the human microbiome market is segmented into drugs, probiotics, prebiotics, and synbiotics. The drugs segment is the fastest-growing segment in the global human microbiome market. This growth can primarily be attributed to factors such as a rising number of microbiome-based drugs in the pipeline and increasing funding for drug development.
Human Microbiome Market, By Type
By type, the human microbiome market is segmented into bacterial consortia transplantation (BCT)/fecal microbiota transplantation (FMT), live biotherapeutic products (LBP), and other microbiome types, which include peptides and metabolites. The LBP segment accounted for the largest share of the human microbiome market in 2024, while the BCT/FMT segment is the fastest-growing segment. Growth in this market segment is driven by the existence of major players commercializing LBPs, a flourishing ecosystem, and increasing consumer demand.
Human Microbiome Market, By Route of Administration
By route of administration, the human microbiome market is segmented into the oral and rectal routes. The oral route of administration segment accounted for the largest share of the human microbiome market in 2024. This segment makes up a larger portion of the human microbiome market because it mainly consists of easier-to-administer human microbiome products such as probiotics, prebiotics, and synbiotics. On the other hand, drugs like fecal microbiota transplants mainly occupy the rectal segment.
Human Microbiome Market, By End User
Based on end user, the human microbiome market is broadly segmented into hospitals & clinics, long-term care facilities, and other end users. In 2024, the hospitals & clinics segment commanded the largest share of the human microbiome market. Hospitals offer fecal microbiota transplants and bacterial consortia transplants for treating dysbiosis caused by various disorders, such as recurrent Clostridioides difficile infections.
REGION
Asia Pacific to be the fastest-growing region in global human microbiome market during forecast period
The Asia Pacific region is expected to record the fastest growth in the human microbiome market during the forecast period. This expansion is driven by increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies in key countries such as China, India, and Japan.
Human Microbiome Market: COMPANY EVALUATION MATRIX
In the human microbiome market matrix, International Flavors & Fragrances Inc. leads with a strong market presence and comprehensive product portfolio, demonstrating a strong commitment to advancing microbiome health solutions globally. Pendulum is gaining traction with specialized solutions and expanding footprints, particularly in gut-health and overall well-being.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Seres Therapeutics (US)
- Ferring B.V. (Switzerland)
- BiomeBank (Australia)
- Seed Health, Inc. (US)
- International Flavors & Fragrances Inc. (US)
- Pendulum (US)
- BioHM Health Inc. (US)
- Actial Farmaceutica SRL (Italy)
- OptiBiotix Health Plc (UK)
- Resbiotic (US)
- Infinant Health Inc. (US),
- BioGaia (Sweden)
- ExeGi Pharma LLC (US)
- Maat Pharma (France)
- Finch Therapeutics Group, Inc. (US)
- Infant Bacterial Therapeutics AB (Sweden)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 0.91 BN |
| Market Forecast in 2031 (Value) | USD 7.09 BN |
| Growth Rate | CAGR of 31.0% from 2025–2031 |
| Years Considered | 2023–2031 |
| Base Year | 2024 |
| Forecast Period | 2025–2031 |
| Units Considered | Value (USD Million) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | By Product: Drugs, Supplements, Diagnostics I By Type: Bacterial Consortia Transplant, Fecal Microbiota transplant, Live Bacteria products, Other Product Types I By Disease: Infectious Diseases, Gastrointestinal Diseases, Endocrine & Metabolic Disorders, Other Diseases I By Route of Administration: Oral, Rectal I By End User: Hospitals & Clinics, Long-term Care Facilities, Other End Users |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
WHAT IS IN IT FOR YOU: Human Microbiome Market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Human Microbiome Market, By Distribution Channel | Market size & forecast for human microbiome market based on type of distribution - Prescription-based Products and OTC Products | Split of Supplements into clinical (prescription/FSMP/medical foods) vs. consumer OTC (wellness probiotics, synbiotics) |
| Human Microbiome Diagnostics Market, By Type | Market size & forecast for human microbiome market based on type of diagnostics - microbiome test and companion diagnostics | Diagnostic TAM assessment |
RECENT DEVELOPMENTS
- June 2025 : Seed Health, Inc. announced the nationwide retail launch of its clinically validated microbiome products at Sprouts Farmers Market. Seed's DS-01 Daily Synbiotic and DS-01 14 Day Gut Reset became available across 450 Sprouts stores in 24 US states and online.
- May 2025 : Resbiotic launched its microbiome-based supplements nationwide at Walmart. Products like resB Lung Support Probiotic and resM Postbiotic became available in Walmart stores across the US and online.
- February 2025 : GluCare Health collaborated with Pendulum Therapeutics to evaluate the impact of Pendulum Glucose Control, a probiotic, on blood sugar levels, weight management, and overall metabolic health.
- February 2025 : Resbiotic launched resM GLP-1 Postbiotic, a metabolic health supplement combining L. plantarum RSB11, chromium, fenugreek, white mulberry leaf, and vitamin B12. Designed to improve glucose control, metabolism, and satiety, the product entered a randomized clinical trial to assess its effects on weight, cravings, and biomarkers.
- January 2025 : Resbiotic Nutrition signed a strategic distribution agreement with Grupo Columbia S.A. de C.V. to commercialize its resB Lung Support Probiotic across Mexico through Laboratorios Columbia.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
34
2
RESEARCH METHODOLOGY
38
3
EXECUTIVE SUMMARY
49
4
PREMIUM INSIGHTS
54
5
MARKET OVERVIEW
Microbiome market thrives on academia-industry collaboration, despite regulatory hurdles and slow therapy adoption.
57
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
Collaborative initiatives between organizations and academia
5.2.1.2
Increasing number of startups/SMEs exploring microbiome
5.2.1.3
Advancements in microbiome sequencing
5.2.2
RESTRAINTS
5.2.2.1
Complex regulatory policies
5.2.2.2
High investments in commercializing microbiome drugs
5.2.3
OPPORTUNITIES
5.2.3.1
Increasing demand for personalized medicines
5.2.3.2
Emergence of postbiotics
5.2.4
CHALLENGES
5.2.4.1
Slow patient adoption of microbiome-based therapies
5.2.4.2
Complexities in developing microbiome therapies
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.3.1
DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
5.3.1.1
Market readiness
5.3.1.2
Adoption
5.3.1.3
Maturity
5.4
PRICING ANALYSIS
5.4.1
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024
5.4.2
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022–2024
5.5
VALUE CHAIN ANALYSIS
5.5.1
HUMAN MICROBIOME DRUGS
5.5.2
HUMAN MICROBIOME SUPPLEMENTS
5.5.3
HUMAN MICROBIOME DIAGNOSTICS
5.6
ECOSYSTEM ANALYSIS
5.6.1
ECOSYSTEM SHIFT
5.6.1.1
Specialized raw material and data suppliers
5.6.1.2
Hot-bet innovator startups
5.6.1.3
Integrated end users and prosumer models
5.6.1.4
Regulatory and quality assurance orchestrators
5.6.1.5
Diagnostics-driven personalization
5.6.1.6
Microbiome-as-a-Service (Maas)
5.6.2
EMERGING BUSINESS MODELS
5.6.2.1
Emerging B2C model
5.6.2.2
Personalized supplements model
5.6.3
INTERCONNECTED MARKET DYNAMICS
5.7
INVESTMENT AND FUNDING SCENARIO
5.7.1
MAJOR INVESTMENTS AND FUNDING BY KEY MARKET PLAYERS
5.7.2
OTHER INVESTMENTS AND FUNDING
5.8
TECHNOLOGY ANALYSIS
5.8.1
KEY TECHNOLOGIES
5.8.1.1
Whole-genome sequencing
5.8.1.2
16s RNA sequencing method
5.8.1.3
Nanopore sequencing
5.8.2
COMPLEMENTARY TECHNOLOGIES
5.8.2.1
Metatranscriptomics
5.8.2.2
Metagenomics
5.8.2.3
Metabolomics
5.8.3
ADJACENT TECHNOLOGIES
5.8.3.1
Sample preparation
5.8.3.2
Data analysis
5.8.3.3
Library synthesis
5.9
PATENT ANALYSIS
5.10
KEY CONFERENCES AND EVENTS, 2025–2026
5.11
CASE STUDY ANALYSIS
5.11.1
EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
5.11.2
ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION
5.11.3
DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS
5.12
TARIFF AND REGULATORY ANALYSIS
5.12.1
TARIFF DATA (HS CODE 3002.90)
5.12.2
REGULATORY LANDSCAPE
5.12.2.1
North America
5.12.2.2
Europe
5.12.2.3
Asia Pacific
5.12.3
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13
PORTER’S FIVE FORCES ANALYSIS
5.13.1
BARGAINING POWER OF SUPPLIERS
5.13.2
BARGAINING POWER OF BUYERS
5.13.3
THREAT OF NEW ENTRANTS
5.13.4
THREAT OF SUBSTITUTES
5.13.5
INTENSITY OF COMPETITIVE RIVALRY
5.14
KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2
BUYING CRITERIA
5.15
PIPELINE ANALYSIS
5.16
IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET
5.16.1
INTRODUCTION
5.16.2
MARKET POTENTIAL OF AI IN HUMAN MICROBIOME MARKET
5.16.3
AI USE CASES
5.16.4
KEY PLAYERS IMPLEMENTING AI
5.16.5
FUTURE OF GENERATIVE AI IN HUMAN MICROBIOME MARKET
5.17
IMPACT OF US TARIFF ON HUMAN MICROBIOME MARKET
5.17.1
KEY TARIFF RATES
5.17.2
PRICE IMPACT ANALYSIS
5.17.3
KEY IMPACT ON COUNTRY/REGION
5.17.3.1
US
5.17.3.2
Europe
5.17.3.3
Asia Pacific
5.17.3.4
Rest of the World
5.17.4
IMPACT ON END-USE INDUSTRY
5.17.4.1
Hospitals and clinics
5.17.4.2
Long-term care facilities
5.18
MANAGING GLP-1 SIDE EFFECTS WITH MICROBIOME INTERVENTIONS
5.19
FUTURE TRENDS IN HUMAN MICROBIOME MARKET
5.19.1
TYPE
5.19.2
DISEASE
5.19.3
END USER
6
HUMAN MICROBIOME MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 41 Data Tables
124
6.1
INTRODUCTION
6.2
DRUGS
6.2.1
GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET
6.3
SUPPLEMENTS
6.3.1
PROBIOTICS
6.3.1.1
Increasing consumer awareness about probiotics for improved gut health and immunity to aid growth
6.3.2
PREBIOTICS
6.3.2.1
Rising development of targeted prebiotics to expedite growth
6.3.3
SYNBIOTICS
6.3.3.1
Growing demand for personalized treatment and rising incidence of dysbiosis to fuel market
6.4
DIAGNOSTICS
6.4.1
INCREASING PRODUCT LAUNCHES AND TECHNOLOGY TRANSFER TO FACILITATE GROWTH
7
HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 18 Data Tables
145
7.1
INTRODUCTION
7.2
BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
7.2.1
ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT GROWTH
7.3
LIVE BACTERIA PRODUCTS (LBP)
7.3.1
INCREASING CONSUMER FOCUS ON PREVENTIVE HEALTH TO AID GROWTH
7.4
OTHER MICROBIOME TYPES
8
HUMAN MICROBIOME MARKET, BY DISEASE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 26 Data Tables
155
8.1
INTRODUCTION
8.2
INFECTIOUS DISEASES
8.2.1
EMERGENCE OF MULTIDRUG-RESISTANT BACTERIA TO FOSTER GROWTH
8.3
GASTROINTESTINAL DISEASES
8.3.1
INCREASING DEMAND FOR PERSONALIZED THERAPIES TO AID GROWTH
8.4
ENDOCRINE & METABOLIC DISORDERS
8.4.1
DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET
8.5
OTHER DISEASES
9
HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 11 Data Tables
169
9.1
INTRODUCTION
9.2
ORAL ROUTE OF ADMINISTRATION
9.2.1
WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO ENCOURAGE GROWTH
9.3
RECTAL ROUTE OF ADMINISTRATION
9.3.1
ABILITY TO RESTORE HEALTHY GUT TO FACILITATE GROWTH
10
HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 1 Data Tables
176
10.1
INTRODUCTION
10.2
STRAIN DEVELOPMENT & OPTIMIZATION
10.2.1
RISING DEMAND FOR TARGETED, STRAIN-SPECIFIC MICROBIOME THERAPIES TO BOOST MARKET
10.3
FERMENTATION & DOWNSTREAM PROCESSING
10.3.1
GROWING DEMAND FOR CLINICAL-STAGE BIOTHERAPEUTICS TO DRIVE MARKET
10.4
FORMULATION & FILL/FINISH
10.4.1
INCREASING STUDIES ON LIVE BIOTHERAPEUTIC PRODUCTS TO PROMOTE GROWTH
10.5
OTHER SERVICES
11
HUMAN MICROBIOME MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
180
11.1
INTRODUCTION
11.2
HOSPITALS & CLINICS
11.2.1
AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT GROWTH
11.3
LONG-TERM CARE FACILITIES
11.3.1
NEED FOR SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
11.4
OTHER END USERS
12
HUMAN MICROBIOME MARKET, BY REGION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 177 Data Tables
191
12.1
INTRODUCTION
12.2
NORTH AMERICA
12.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2
US
12.2.2.1
Favorable government initiatives and booming diagnostics sector to drive market
12.2.3
CANADA
12.2.3.1
Increasing prevalence of chronic diseases to expedite growth
12.3
EUROPE
12.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2
GERMANY
12.3.2.1
Rapid increase in government and private funding to propel market
12.3.3
UK
12.3.3.1
Significant government investments in microbiome research and presence of microbiome companies to propel growth
12.3.4
FRANCE
12.3.4.1
Growing focus on developing new products and services using microbiome data to boost market
12.3.5
ITALY
12.3.5.1
Rise in research activities to encourage growth
12.3.6
SPAIN
12.3.6.1
Favorable microbiome research landscape to support growth
12.3.7
REST OF EUROPE
12.4
ASIA PACIFIC
12.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2
CHINA
12.4.2.1
Rapidly expanding healthcare industry to accelerate growth
12.4.3
JAPAN
12.4.3.1
Booming geriatric population to contribute to growth
12.4.4
INDIA
12.4.4.1
Increasing number of human microbiome diagnostic companies to augment growth
12.4.5
SOUTH KOREA
12.4.5.1
Booming bio-health market to advance growth
12.4.6
AUSTRALIA
12.4.6.1
Growing number of product approvals to boost markt
12.4.7
REST OF ASIA PACIFIC
12.5
LATIN AMERICA
12.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2
BRAZIL
12.5.2.1
Rising probiotics demand to drive market
12.5.3
REST OF LATIN AMERICA
12.6
MIDDLE EAST
12.6.1
MACROECONOMIC OUTLOOK IN MIDDLE EAST
12.6.2
GCC COUNTRIES
12.6.2.1
Saudi Arabia
12.6.2.2
UAE
12.6.2.3
Rest of GCC countries
12.6.3
REST OF MIDDLE EAST
12.7
AFRICA
12.7.1
INCREASING STUDIES AND INITIATIVES ON MICROBIOME TO PROMOTE GROWTH
12.7.2
MACROECONOMIC OUTLOOK FOR AFRICA
13
COMPETITIVE LANDSCAPE
Discover how top players and startups dominate the human microbiome market through strategic maneuvers.
269
13.1
INTRODUCTION
13.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
13.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET
13.3
REVENUE ANALYSIS, 2022–2024
13.4
MARKET SHARE ANALYSIS, 2024
13.5
COMPANY VALUATION AND FINANCIAL METRICS
13.6
BRAND/PRODUCT COMPARISON
13.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.7.1
STARS
13.7.2
EMERGING LEADERS
13.7.3
PERVASIVE PLAYERS
13.7.4
PARTICIPANTS
13.7.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.7.5.1
Company footprint
13.7.5.2
Region footprint
13.7.5.3
Product footprint
13.7.5.4
Type footprint
13.7.5.5
Disease footprint
13.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.8.1
PROGRESSIVE COMPANIES
13.8.2
RESPONSIVE COMPANIES
13.8.3
DYNAMIC COMPANIES
13.8.4
STARTING BLOCKS
13.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
13.8.5.1
Detailed list of key startups/SMEs
13.8.5.2
Competitive benchmarking of key emerging players/startups
13.9
COMPETITIVE SCENARIO
13.9.1
PRODUCT LAUNCHES AND APPROVALS
13.9.2
DEALS
13.9.3
EXPANSIONS
14
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
294
14.1
KEY PLAYERS
14.1.1
INTERNATIONAL FLAVORS & FRAGRANCES INC.
14.1.1.1
Business overview
14.1.1.2
Products offered
14.1.1.3
Recent developments
14.1.1.4
MnM view
14.1.2
SEED HEALTH, INC.
14.1.3
SERES THERAPEUTICS
14.1.4
FERRING B.V.
14.1.5
PENDULUM
14.1.6
OPTIBIOTIX HEALTH PLC
14.1.7
BIOGAIA
14.1.8
MAAT PHARMA
14.1.9
MICROBA
14.1.10
BIOMEBANK
14.1.11
BIOHM HEALTH
14.1.12
ACTIAL FARMACEUTICA SRL
14.1.13
RESBIOTIC
14.1.14
INFINANT HEALTH INC.
14.1.15
EXEGI PHARMA
14.1.16
FINCH THERAPEUTICS GROUP, INC.
14.1.17
INFANT BACTERIAL THERAPEUTICS AB
14.1.18
VIOME LIFESCIENCES
14.1.19
GENOVA DIAGNOSTICS
14.2
OTHER PLAYERS
14.2.1
AOBIOME
14.2.2
GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
14.2.3
NUBIYOTA
14.2.4
OXTHERA
14.2.5
NEXBIOME
14.2.6
VEDANTA BIOSCIENCES, INC.
14.2.7
ENTEROME
14.2.8
APSEN FARMACÊUTICA
14.2.9
METAGEN, INC.
14.2.10
SNIPR BIOME
14.2.11
MIKROBIOMIK
14.2.12
SYNLOGIC
14.2.13
GENETIC ANALYSIS
14.2.14
METABIOMICS
14.2.15
SUN GENOMICS, INC.
15
APPENDIX
363
15.1
DISCUSSION GUIDE
15.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3
CUSTOMIZATION OPTIONS
15.4
RELATED REPORTS
15.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
HUMAN MICROBIOME MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
TABLE 3
HUMAN MICROBIOME MARKET: RISK ANALYSIS
TABLE 4
HUMAN MICROBIOME MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 5
INDUSTRY COLLABORATIONS IN HUMAN MICROBIOME MARKET, 2022–2024
TABLE 6
LIST OF STARTUPS/SMES IN HUMAN MICROBIOME MARKET
TABLE 7
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)
TABLE 8
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022–2024 (USD)
TABLE 9
HUMAN MICROBIOME MARKET: MAJOR INVESTMENT AND FUNDING, 2022–2024
TABLE 10
HUMAN MICROBIOME MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024
TABLE 11
HUMAN MICROBIOME MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 12
TARIFF DATA FOR HS CODE 3002.90
TABLE 13
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17
REGULATORY LANDSCAPE OF LIVE BIOTHERAPEUTIC PRODUCTS
TABLE 18
HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 19
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 20
KEY BUYING CRITERIA, BY END USER
TABLE 21
KEY PLAYERS IMPLEMENTING AI IN HUMAN MICROBIOME
TABLE 22
COMPANIES LEVERAGING AI IN HUMAN MICROBIOME MARKET
TABLE 23
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 24
KEY PRODUCT-RELATED TARIFF: PHARMACEUTICAL PRODUCTS, MISCELLANEOUS EDIBLE PREPARATIONS, AND PRODUCTS OF ANIMAL ORIGIN
TABLE 25
CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
TABLE 26
HUMAN MICROBIOME SUPPLEMENTS POSITIONED AS GLP-1 SUPPORT
TABLE 27
HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 28
HUMAN MICROBIOME DRUGS IN CLINICAL STAGE
TABLE 29
HUMAN MICROBIOME DRUGS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 30
NORTH AMERICA: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 31
ASIA PACIFIC: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 32
HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 33
HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 34
NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 35
EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 36
ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 37
LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 38
MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 39
GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 40
HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 41
NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 42
EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 43
ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 44
LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 45
MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 46
GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 47
HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 48
NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 49
EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 50
ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 51
LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 52
MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 53
GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 54
HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 55
NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 56
EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 57
ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 58
LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 59
MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 60
GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 61
HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 62
NORTH AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 63
EUROPE: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 64
ASIA PACIFIC: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 65
LATIN AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 66
MIDDLE EAST: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 67
GCC COUNTRIES: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 68
HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 69
HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY REGION, 2023–2031 (USD MILLION)
TABLE 70
NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 71
ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 72
HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023–2031 (USD MILLION)
TABLE 73
NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 74
EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 75
ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 76
LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 77
MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023–2031 (USD MILLION)
TABLE 78
GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 79
HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023–2031 (USD MILLION)
TABLE 80
NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 81
EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 82
ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 83
LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 84
MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023–2031 (USD MILLION)
TABLE 85
GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 86
HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 87
DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
TABLE 88
HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 89
NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 90
ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 91
HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 92
NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 93
EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 94
ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 95
LATIN AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 96
MIDDLE EAST: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 97
GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 98
HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 99
NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 100
EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 101
ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 102
LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 103
MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 104
GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 105
HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 106
NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 107
EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 108
ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 109
LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 110
MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2031 (USD MILLION)
TABLE 111
GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 112
HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 113
HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION)
TABLE 114
NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 115
EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 116
ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 117
LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 118
MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION)
TABLE 119
GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 120
HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION)
TABLE 121
NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 122
ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 123
HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE,2023–2031 (USD MILLION)
TABLE 124
HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 125
HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 126
NORTH AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 127
EUROPE: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 128
ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 129
LATIN AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 130
MIDDLE EAST: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2031 (USD MILLION)
TABLE 131
GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 132
HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2031 (USD MILLION)
TABLE 133
NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 134
EUROPE: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 135
ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 136
LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 137
MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2031 (USD MILLION)
TABLE 138
GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 139
HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 140
NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 141
EUROPE: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 142
ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 143
LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 144
MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION)
TABLE 145
GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 146
HUMAN MICROBIOME MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 147
NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 148
NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 149
NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 150
NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 151
NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 152
NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 153
NORTH AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 154
NORTH AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 155
US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 156
US: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 157
US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 158
US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 159
US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 160
US: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 161
CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 162
CANADA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 163
CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 164
CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 165
CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 166
CANADA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 167
EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 168
EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 169
EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 170
EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 171
EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 172
EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 173
EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 174
EUROPE: KEY MACROECONOMIC INDICATORS
TABLE 175
GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 176
GERMANY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 177
GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 178
GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 179
GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 180
GERMANY: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 181
UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 182
UK: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 183
UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 184
UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 185
UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 186
UK: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 187
HUMAN MICROBIOME STARTUPS IN FRANCE
TABLE 188
FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 189
FRANCE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 190
FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 191
FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 192
FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 193
FRANCE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 194
ITALY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 195
ITALY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 196
ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 197
ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 198
ITALY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 199
ITALY: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 200
SPAIN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 201
SPAIN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 202
SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 203
SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 204
SPAIN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 205
SPAIN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 206
REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 207
REST OF EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 208
REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 209
REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 210
REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 211
REST OF EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 212
ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 213
ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 214
ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 215
ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 216
ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 217
ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 218
ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 219
ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 220
CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 221
CHINA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 222
CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 223
CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 224
CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 225
CHINA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 226
JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 227
JAPAN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 228
JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 229
JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 230
JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 231
JAPAN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 232
HUMAN MICROBIOME DIAGNOSTICS COMPANIES IN INDIA
TABLE 233
INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 234
INDIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 235
INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 236
INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 237
INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 238
INDIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 239
SOUTH KOREA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 240
SOUTH KOREA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 241
SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 242
SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 243
SOUTH KOREA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 244
SOUTH KOREA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 245
AUSTRALIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 246
AUSTRALIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 247
AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 248
AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 249
AUSTRALIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 250
AUSTRALIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 251
REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 252
REST OF ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 253
REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 254
REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 255
REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 256
REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 257
LATIN AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 258
LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 259
LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 260
LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 261
LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 262
LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 263
LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 264
LATIN AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 265
BRAZIL: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 266
BRAZIL: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 267
BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 268
BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 269
BRAZIL: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 270
BRAZIL: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 271
REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 272
REST OF LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 273
REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 274
REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 275
REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 276
REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 277
MIDDLE EAST: HUMAN MICROBIOME MARKET, BY REGION, 2023–2031 (USD MILLION)
TABLE 278
MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 279
MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 280
MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 281
MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 282
MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 283
MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 284
MIDDLE EAST: KEY MACROECONOMIC INDICATORS
TABLE 285
GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
TABLE 286
GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 287
GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 288
GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 289
GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 290
GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 291
GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 292
SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 293
SAUDI ARABIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 294
SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 295
SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 296
SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 297
SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 298
UAE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 299
UAE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 300
UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 301
UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 302
UAE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 303
UAE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 304
REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 305
REST OF GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 306
REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 307
REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 308
REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 309
REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 310
REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 311
REST OF MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 312
REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 313
REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 314
REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 315
REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 316
AFRICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION)
TABLE 317
AFRICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 318
AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION)
TABLE 319
AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION)
TABLE 320
AFRICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION)
TABLE 321
AFRICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION)
TABLE 322
AFRICA: KEY MACROECONOMIC INDICATORS
TABLE 323
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET, JANUARY 2022–JULY 2025
TABLE 324
HUMAN MICROBIOME MARKET: DEGREE OF COMPETITION, 2024
TABLE 325
HUMAN MICROBIOME MARKET: REGION FOOTPRINT
TABLE 326
HUMAN MICROBIOME MARKET: DRUG & SUPPLEMENT FOOTPRINT
TABLE 327
HUMAN MICROBIOME MARKET: TYPE FOOTPRINT
TABLE 328
HUMAN MICROBIOME MARKET: DISEASE FOOTPRINT
TABLE 329
HUMAN MICROBIOME MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 330
HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 331
HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 332
HUMAN MICROBIOME MARKET: DEALS, JANUARY 2022–JULY 2025
TABLE 333
HUMAN MICROBIOME MARKET: EXPANSIONS, JANUARY 2022–JULY 2025
TABLE 334
INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW
TABLE 335
INTERNATIONAL FLAVORS & FRAGRANCES INC.: PRODUCTS OFFERED
TABLE 336
INTERNATIONAL FLAVORS & FRAGRANCES INC.: DEALS, JANUARY 2022–JULY 2025
TABLE 337
INTERNATIONAL FLAVORS & FRAGRANCES INC.: EXPANSIONS, JANUARY 2022–JULY 2025
TABLE 338
SEED HEALTH, INC.: COMPANY OVERVIEW
TABLE 339
SEED HEALTH, INC.: PRODUCTS OFFERED
TABLE 340
SEED HEALTH, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 341
SEED HEALTH, INC.: DEALS, JANUARY 2022–JULY 2025
TABLE 342
SEED HEALTH, INC.: EXPANSIONS, JANUARY 2022−JULY 2025
TABLE 343
SERES THERAPEUTICS: COMPANY OVERVIEW
TABLE 344
SERES THERAPEUTICS: PRODUCTS OFFERED
TABLE 345
SERES THERAPEUTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 346
SERES THERAPEUTICS: DEALS, JANUARY 2022–JULY 2025
TABLE 347
FERRING B.V.: COMPANY OVERVIEW
TABLE 348
FERRING B.V.: PRODUCTS OFFERED
TABLE 349
FERRING B.V.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 350
FERRING B.V.: DEALS, JANUARY 2022–JULY 2025
TABLE 351
PENDULUM: COMPANY OVERVIEW
TABLE 352
PENDULUM: PRODUCTS OFFERED
TABLE 353
PENDULUM: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 354
PENDULUM: DEALS, JANUARY 2022–JULY 2025
TABLE 355
OPTIBIOTIX HEALTH PLC: COMPANY OVERVIEW
TABLE 356
OPTIBIOTIX HEALTH PLC: PRODUCTS OFFERED
TABLE 357
OPTIBIOTIX HEALTH PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 358
OPTIBIOTIX HEALTH PLC: DEALS, JANUARY 2022–JULY 2025
TABLE 359
BIOGAIA: COMPANY OVERVIEW
TABLE 360
BIOGAIA: PRODUCTS OFFERED
TABLE 361
BIOGAIA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 362
BIOGAIA: DEALS, JANUARY 2022–JULY 2025
TABLE 363
BIOGAIA: EXPANSIONS, JANUARY 2022–JULY 2025
TABLE 364
MAAT PHARMA: COMPANY OVERVIEW
TABLE 365
MAAT PHARMA: PRODUCTS OFFERED
TABLE 366
MAAT PHARMA: DEALS, JANUARY 2022–JULY 2025
TABLE 367
MAAT PHARMA: OTHER DEVELOPMENTS, JANUARY 2022−JULY 2025
TABLE 368
MICROBA: COMPANY OVERVIEW
TABLE 369
MICROBA: PRODUCTS OFFERED
TABLE 370
MICROBA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 371
BIOMEBANK: COMPANY OVERVIEW
TABLE 372
BIOMEBANK: PRODUCTS OFFERED
TABLE 373
BIOMEBANK: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 374
BIOMEBANK: DEALS, JANUARY 2022–JULY 2025
TABLE 375
BIOMEBANK: EXPANSIONS, JANUARY 2022–JULY 2025
TABLE 376
BIOHM HEALTH: COMPANY OVERVIEW
TABLE 377
BIOHM HEALTH: PRODUCTS OFFERED
TABLE 378
BIOHM HEALTH: DEALS, JANUARY 2022–JULY 2025
TABLE 379
ACTIAL FARMACEUTICA SRL: COMPANY OVERVIEW
TABLE 380
ACTIAL FARMACEUTICA SRL: PRODUCTS OFFERED
TABLE 381
RESBIOTIC: COMPANY OVERVIEW
TABLE 382
RESBIOTIC: PRODUCTS OFFERED
TABLE 383
RESBIOTIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 384
RESBIOTIC: DEALS, JANUARY 2022–JULY 2025
TABLE 385
RESBIOTIC: EXPANSIONS, JANUARY 2022–JULY 2025
TABLE 386
INFINANT HEALTH INC.: COMPANY OVERVIEW
TABLE 387
INFINANT HEALTH INC.: PRODUCTS OFFERED
TABLE 388
INFINANT HEALTH INC.: DEALS, JANUARY 2022–JULY 2025
TABLE 389
EXEGI PHARMA: COMPANY OVERVIEW
TABLE 390
EXEGI PHARMA: PRODUCTS OFFERED
TABLE 391
EXEGI PHARMA: DEALS, JANUARY 2022–JULY 2025
TABLE 392
FINCH THERAPEUTICS GROUP, INC.: COMPANY OVERVIEW
TABLE 393
FINCH THERAPEUTICS GROUP, INC.: PRODUCTS OFFERED
TABLE 394
FINCH THERAPEUTICS GROUP, INC.: DEALS, JANUARY 2022–JULY 2025
TABLE 395
INFANT BACTERIAL THERAPEUTICS AB: COMPANY OVERVIEW
TABLE 396
INFANT BACTERIAL THERAPEUTICS AB: PRODUCTS OFFERED
TABLE 397
VIOME LIFESCIENCES: COMPANY OVERVIEW
TABLE 398
VIOME LIFESCIENCES: PRODUCTS OFFERED
TABLE 399
VIOME LIFESCIENCES: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025
TABLE 400
GENOVA DIAGNOSTICS: COMPANY OVERVIEW
TABLE 401
GENOVA DIAGNOSTICS: PRODUCTS OFFERED
TABLE 402
AOBIOME: COMPANY OVERVIEW
TABLE 403
GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
TABLE 404
NUBIYOTA: COMPANY OVERVIEW
TABLE 405
OXTHERA: COMPANY OVERVIEW
TABLE 406
NEXBIOME: COMPANY OVERVIEW
TABLE 407
VEDANTA BIOSCIENCES, INC.: COMPANY OVERVIEW
TABLE 408
ENTEROME: COMPANY OVERVIEW
TABLE 409
APSEN FARMACÊUTICA: COMPANY OVERVIEW
TABLE 410
METAGEN, INC.: COMPANY OVERVIEW
TABLE 411
SNIPR BIOME: COMPANY OVERVIEW
TABLE 412
MIKROBIOMIK: COMPANY OVERVIEW
TABLE 413
SYNLOGIC: COMPANY OVERVIEW
TABLE 414
GENETIC ANALYSIS: COMPANY OVERVIEW
TABLE 415
METABIOMICS: COMPANY OVERVIEW
TABLE 416
SUN GENOMICS, INC.: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
HUMAN MICROBIOME MARKET SEGMENTATION AND REGIONAL SCOPE
FIGURE 2
RESEARCH DESIGN
FIGURE 3
HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES
FIGURE 4
HUMAN MICROBIOME MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 5
MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024
FIGURE 6
ILLUSTRATIVE EXAMPLE OF INTERNATIONAL FLAVORS & FRAGRANCES INC.: REVENUE SHARE ANALYSIS, 2024
FIGURE 7
MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 8
MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 9
HUMAN MICROBIOME MARKET: CAGR PROJECTIONS
FIGURE 10
DATA TRIANGULATION METHODOLOGY
FIGURE 11
HUMAN MICROBIOME MARKET, BY PRODUCT, 2025 VS. 2031 (USD MILLION)
FIGURE 12
HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2025 VS. 2031 (USD MILLION)
FIGURE 13
HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2024 VS. 2030 (USD MILLION)
FIGURE 14
HUMAN MICROBIOME MARKET, BY DISEASE, 2025 VS. 2031 (USD MILLION)
FIGURE 15
HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2031 (USD MILLION)
FIGURE 16
HUMAN MICROBIOME MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
FIGURE 17
HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 18
RISING DEMAND FOR PERSONALIZED MEDICINE AND ADVANCEMENTS IN MICROBIOME SEQUENCING TO DRIVE MARKET
FIGURE 19
US AND LIVE BACTERIA PRODUCTS (LBP) SEGMENT LED NORTH AMERICAN MARKET IN 2024
FIGURE 20
BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 21
US TO DOMINATE GLOBAL MARKET DURING FORECAST PERIOD
FIGURE 22
HOSPITALS & CLINICS SEGMENT TO HOLD LARGEST MARKET SHARE IN 2025
FIGURE 23
HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 24
COMMERCIALIZATION ASPECTS OF MICROBIOMES FOR DRUGS VS. SUPPLEMENTS
FIGURE 25
HUMAN MICROBIOME MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 26
DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
FIGURE 28
AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY KEY PLAYER, 2024 (USD)
FIGURE 29
AVERAGE SELLING PRICE OF HUMAN MICROBIOME DIAGNOSTICS, BY KEY PLAYER, 2024 (USD)
FIGURE 30
AVERAGE SELLING PRICE TREND OF HUMAN MICROBIOME SUPPLEMENTS & DIAGNOSTICS, BY TYPE, 2022–2024 (USD)
FIGURE 31
AVERAGE SELLING PRICE OF HUMAN MICROBIOME SUPPLEMENTS, BY REGION, 2024 (USD)
FIGURE 32
VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME DRUGS
FIGURE 33
VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME SUPPLEMENTS
FIGURE 34
VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME DIAGNOSTICS
FIGURE 35
HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS
FIGURE 36
HUMAN MICROBIOME MARKET: INVESTMENT AND FUNDING SCENARIO, 2022–2024
FIGURE 37
HUMAN MICROBIOME MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024
FIGURE 38
REGULATORY LANDSCAPE OF LIVE BACTERIA PRODUCTS (LBP)
FIGURE 39
HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 40
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
FIGURE 41
KEY BUYING CRITERIA, BY END USER
FIGURE 42
HUMAN MICROBIOME PIPELINE, BY DISEASE
FIGURE 43
HUMAN MICROBIOME PIPELINE, BY PHASE
FIGURE 44
HUMAN MICROBIOME PIPELINE, BY REGION
FIGURE 45
IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET
FIGURE 46
AI USE CASES
FIGURE 47
NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
FIGURE 48
ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
FIGURE 49
REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME MARKET, 2022–2024 (USD MILLION)
FIGURE 50
MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME MARKET, 2024
FIGURE 51
EV/EBITDA OF KEY PLAYERS
FIGURE 52
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
FIGURE 53
HUMAN MICROBIOME MARKET: BRAND/PRODUCT COMPARISON
FIGURE 54
HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 55
HUMAN MICROBIOME MARKET: COMPANY FOOTPRINT
FIGURE 56
HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 57
INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2024)
FIGURE 58
SERES THERAPEUTICS: COMPANY SNAPSHOT (2023)
FIGURE 59
FERRING B.V.: COMPANY SNAPSHOT (2024)
FIGURE 60
OPTIBIOTIX HEALTH PLC: COMPANY SNAPSHOT (2024)
FIGURE 61
BIOGAIA: COMPANY SNAPSHOT (2024)
FIGURE 62
MAAT PHARMA: COMPANY SNAPSHOT (2024)
FIGURE 63
MICROBA: COMPANY SNAPSHOT (2024)
FIGURE 64
FINCH THERAPEUTICS GROUP, INC.: COMPANY SNAPSHOT (2023)
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global human microbiome market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include World Health Organization (WHO), Human Microbiome Project (HMP), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Annual Reports, SEC Filings, Investor Presentations, Research Journals, Press Releases, and financial statements. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate & validate the total size of the human microbiome market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
The human microbiome encompasses the collective genetic material of diverse microorganisms residing within the human body, known as the metagenome. This includes bacteria, fungi, protozoans, non-living viruses, and various single-celled organisms. These microorganisms play a crucial role in human physiology, influencing metabolic and immune functions. Found within human tissues, the microbiome is a focal point of research for medical advancements and analytical techniques. It is applied in probiotics, prebiotics, pharmaceuticals, and therapeutic systems to address conditions such as diabetes, obesity, and cancer, as well as a range of metabolic, gastrointestinal, neurological, central nervous system, and autoimmune disorders.
The study provides an in-depth analysis of the Human Microbiome market based on contemporary market trends and developments, and its potential growth from 2025 to 2031. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key Human Microbiome service providers.
Stakeholders
- Manufacturers and Distributors of Human Microbiome Products
- Pharmaceutical and Biotechnology Companies
- Market Research and Consulting Firms
- R&D Centers
- Researchers and Scientists
- Academic & Research Institutes
- Hospitals & Clinics
- Long-term Care Centers
- Specialty Care Centers
- Outpatient Care Centers
Report Objectives
- To define, describe, and forecast the human microbiome market based on products, disease, drugs & supplements type, drugs & supplements route of administration, end user, manufacturing services and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall human microbiome market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the human microbiome market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the human microbiome market
- To benchmark players within the human microbiome market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Key Questions Addressed by the Report
Who are the key players in the human microbiome market?
Key players include Seres Therapeutics, Inc. (US), Ferring B.V. (Switzerland), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), and Pendulum (US).
Which supplement segment dominates the human microbiome market?
The probiotics segment dominated the human microbiome supplements market in 2024.
Which disease segment of the global human microbiome market is expected to witness the highest growth?
The gastrointestinal diseases segment is expected to witness the highest growth, driven by demand for personalized therapies, regulatory approvals, and a strong clinical pipeline.
What is the size of the human microbiome market?
The human microbiome market is estimated to be valued at USD 1.40 million in 2025.
What is the growth rate of the human microbiome market?
The global human microbiome market is expected to grow at a CAGR of 31.0% during the forecast period of 2025–2031.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Human Microbiome Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Before You Go
Expand Beyond Human Microbiome Market
Explore the top 20 industries influencing your market growth
Human and AI Powered Market Intelligence
Find Untapped Markets
Growth opportunities and latent adjacency in Human Microbiome Market